Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

PrEP news

Show

From To
Drug Resistance, While Rare, Can Occur After Contracting HIV on PrEP

For the first time, a study has shown that, although rare, resistance to Truvada can develop if someone contracts HIV while taking the drug as PrEP.

Published
16 January 2015
From
AIDSMeds
Long-acting drug effectively prevents HIV-like infection in monkeys

Two new studies, including one conducted by researchers at the Aaron Diamond AIDS Research Center (ADARC) and Rockefeller University, published today (January 15) in Science Translational Medicine, show that long-acting cabotegravir injections are highly protective in a monkey model of vaginal transmission of a virus similar to HIV. This study was first reported by Aidsmap last year - see http://www.aidsmap.com/Monkey-studies-confirm-viability-of-injectable-PrEP-drug/page/2832825/ . A study in humans in now underway.

Published
16 January 2015
From
Rockefeller University press release
My Gonorrhea Nostalgia

A common objection to the use of pre-exposure prophylaxis (PrEP) is that taking a pill to prevent HIV does not guard against other STI’s and therefore condoms must continue to be used. But when did avoiding every possible STI become the new goal for gay sexual behavior? Syphilis, chlamydia, and gonorrhea are all easily treated and cured.

Published
14 January 2015
From
My Fabulous Disease
NYC Health Dept. Launches PrEP, PEP Outreach Campaign

To boost awareness of pre- and post-exposure prophylaxis (PrEP and PEP) to prevent HIV infection, the NYC Department of Health has launched an outreach program targeted to 600 doctors.

Published
14 January 2015
From
Poz magazine news
PrEP Version 1.1, 2.0, and Beyond

Peter Staley: The treatment to prevent HIV infections faces inaccurate comparisons to other meds and the same fearful objections as ‘the pill’ did in the ’60s.

Published
07 January 2015
From
The Advocate
PrEP works in women using injectable hormonal contraceptives and in their male sex partners

Preexposure prophylaxis (PrEP) with tenofovir or tenofovir/emtricitabine proved as effective in women using the injectable hormonal contraceptive depot medroxyprogesterone acetate (DMPA) as in women using no hormonal contraceptive. The same proved true of men whose female sex partners were using DMPA.

Published
07 January 2015
From
International AIDS Society
Who’s to blame for misuse of HIV drugs in Kenya?

Reports of sex workers misusing HIV drugs have left activists wondering if the government invested enough in HIV education before purchasing medicine, worth 4 billion Kenyan shilling. Many sex workers say clients prefer to have unprotected sex and will pay more money for it. This being a business, the women often choose to have unprotected sex, then rush to a public hospital for post-exposure prophylaxis medication, claiming they have been raped or had a burst condom. Some sex workers have also expressed uncertainties about the sustainability of the project, so they go to different hospitals and stockpile the medication, just in case it is no longer available in public hospitals.

Published
07 January 2015
From
Key Correspondents
AIDS Healthcare Foundation Continues Anti-PrEP Rhetoric With New Ad

Justin considers himself a “reformed bug chaser. I want to take care of myself now. Using PrEP isn’t for me to be a whore. It’s one of the valuable options out there to protect myself from HIV,” he said. But added, “I am still going to bareback.” He’s only been on the once a day blue pill for a couple of months. He admits that the first month he missed four to five of his doses. But said he was going to work on better adherence in the future by using sticky notes and setting alarms on his phone to remind him. South Florida Gay News caught up with him a month later when he said he had only missed one to two doses the second month.

Published
29 December 2014
From
South Florida Gay News
Tenofovir-based HIV PrEP does not harm kidneys

Men and women without HIV infection who use tenofovir-based pre-exposure prophylaxis (PrEP) develop significant but not clinically relevant declines in kidney function, according to the largest study to date to look at the issue.

Published
26 December 2014
From
Medscape (requires free registration)
Re-Thinking Risk Compensation: A Conversation with Kim Koester

"When we fixate on risk compensation, which assumes that PrEP replaces or substitutes prior protective behaviors it undermines or marginalizes a far more pervasive reality and that is that men are gravitating towards PrEP as an additive element. Men are seeking additional reassurance and protection from HIV. From the perspective of men who see themselves as adopting safer ways of having sex, in terms of HIV prevention, the notion of risk compensation is offensive and confusing."

Published
19 December 2014
From
BETA blog
← First12345...36Next →

Filter by country